Application of complex of parietic acid or parietic acid compounds and arginine in preparation of medicines for treating vascular complications of diabetes

A technology for diabetic blood vessels and rhein is applied in the application field of rhein or a compound of rhein and arginine in the preparation of medicines for treating diabetic vascular complications, and can solve problems such as male sexual dysfunction.

Inactive Publication Date: 2013-06-26
ZHEJIANG CHINESE MEDICAL UNIV MEDICAL PIECES
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0029] The above inventions have not yet involved the use of rhein or rhein compound compounds to treat diabetic complications, including the treatment of diabetic cardiomyopathy; diabetic macroangiopathy; male sexual dysfunction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of complex of parietic acid or parietic acid compounds and arginine in preparation of medicines for treating vascular complications of diabetes
  • Application of complex of parietic acid or parietic acid compounds and arginine in preparation of medicines for treating vascular complications of diabetes
  • Application of complex of parietic acid or parietic acid compounds and arginine in preparation of medicines for treating vascular complications of diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0094] Example 1, the compound of rhein and arginine (macroarginic acid) treats diabetic cardiomyopathy.

[0095] Diabetes was induced in rats by intraperitoneal injection of streptozotocin 65mg / kg. Blood sugar was as high as 25mM and maintained for 8 weeks. After 4 weeks, diabetic complications had appeared. The untreated group continued to develop. The treatment group was administered in the last 4 weeks (mg / kg, intragastric administration): positive drug aminoguanidine 100, and 3 doses of sarginic acid: 50 mg / kg, 100 mg / kg, 200 mg / kg. Although the untreated diabetic group did not receive medication, they controlled their food intake and were given dietary control treatments to obtain appropriate treatment.

[0096] Pharmacodynamic observation: It consists of macroscopic main pharmacodynamic indicators, expression of important bioactive molecules (mRNA, and protein) in diseased cells and other indicators.

[0097] Sarginic acid restored the above indicators to the normal...

Embodiment 2

[0099] Example 2, the treatment of diabetic macroangiopathy with sarginic acid. Basically the same as Example 1,

[0100] Diabetes was induced in rats by intraperitoneal injection of streptozotocin 65mg / kg. Blood sugar was as high as 25mM and maintained for 8 weeks. After 4 weeks, diabetic complications had appeared. The untreated group continued to develop. The treatment group was administered in the last 4 weeks (mg / kg, intragastric administration): positive drug aminoguanidine 100, and 3 doses of sarginic acid: 50 mg / kg, 100 mg / kg, 200 mg / kg. Although the untreated diabetic group did not receive medication, they controlled their food intake and were given dietary control treatments to obtain appropriate treatment.

[0101] The vasodilation function and NO bioavailability were restored after 4 weeks of treatment with sarginic acid and aminoguanidine. At the same time, the molecular biological targets abnormally expressed in the blood vessel wall are basically restored t...

Embodiment 3

[0103] Example 3, the treatment of diabetic nephropathy with macrospermic acid.

[0104] Diabetes was induced in rats by intraperitoneal injection of streptozotocin 65mg / kg. Blood sugar was as high as 25mM and maintained for 8 weeks. After 4 weeks, diabetic complications had appeared. The untreated group continued to develop. The treatment group was administered in the last 4 weeks (mg / kg, gavage): positive drug aminoguanidine 100, 3 dosage groups of spermatic acid: 50mg / kg, 100mg / kg, 200mg / kg. Although the untreated group of diabetes did not take drugs, they controlled their food intake and were given diet control treatment to obtain appropriate treatment.

[0105]The trace protein in 24h urine of rats with diabetic nephropathy increased significantly, and the creatinine and non-protein nitrogen in blood increased, suggesting: diabetic nephropathy. At the same time, the molecular biological indicators: the gene and protein expression of PPARa in the kidney, the expression...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of complex of parietic acid or parietic acid compounds and arginine in preparation of medicines for treating vascular complications of diabetes. The vascular complications of diabetes mean diabetic great vascular complications or diabetic microangiopathy and comprise diabetic testopathy, sexual debility of diabetic complications (comprising diabetic testopathy and diabetic impotence), diabetic retinopathy and diabetic neuropathy. The complex is abbreviated as Dajingsuan which is a novel crystallized compound and enters into body to release parietic acid and arginine; the solubility of parietic acid is changed, so that the bioavailability is improved and the stability is good. A novel structural characteristic is endowed to a parent compound of parietic acid; Dajingsuan enters into body to release parietic acid and arginine, so that the function of parietic acid which inhibits inflammatory factors: NFkB, TNF alpha, ROS, EGF and the like to regulate the endothelin system is exerted.

Description

[0001] This application is a divisional application. [0002] The application number of the original application is: 201010115021X; the application date is: February 26, 2010; the title of the invention is: the application of rhein or a complex of rhein compounds and arginine in the preparation of drugs for treating diabetic complications. [0003] The following instructions, except for the subject matter of the invention, are all original texts of the original instructions. technical field [0004] The invention relates to the application of rhein or the complex of rhein compounds and arginine in the preparation of medicines for treating diabetic complications. Background technique [0005] Diabetes and its complications are common and frequently-occurring diseases. The incidence of diabetes remains high, showing a trend of high incidence. The incidence rate in China is higher. Diabetes is mainly type II, which affects the middle-aged and elderly people. It is highly pat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/192A61K47/48A61P9/10A61P15/00A61P15/10A61P25/28
Inventor 丛晓东戴德哉张云戴茵
Owner ZHEJIANG CHINESE MEDICAL UNIV MEDICAL PIECES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap